An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

Completed · Phase 3 · Has a placebo group

Conditions studied: Thyroid Eye Disease

In brief

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).

Key facts

Study ID
NCT06021054
Run by
Viridian Therapeutics, Inc.
People needed
188
Starts
2023-11-14
Expected to finish
2025-07-25
Last updated by the study team
2025-10-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.